Nasdaq · CIK 0001701108
SPRO Spero Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Sep 3, 2025. Close $1.20 on Oct 9, 2026, +8% from the 52-week low and -60% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
SPROOct 9, 2026 · close 1.20
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Spero Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Timothy Keutzer Chief Operating Officer sell | $3,339 1,695 shares | -0% | +257% from low-34% from high | |
| 23Weak | Ankit Mahadevia director sell | $13k 6,572 shares | -1% | +257% from low-34% from high | |
| 26Weak | Timothy Keutzer Chief Operating Officer sell | $44k 56,537 shares | -7% | - | |
| 29Weak | Esther Rajavelu CFO & CBO sell | $53k 40,596 shares | -10% | - |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | Ankit Mahadevia director | SOpen-market sale Common Stock | -6,572 | $1.97 | $13k | 703,294 | Sep 3, 2025 |
| Aug 28, 2025 | Timothy Keutzer Chief Operating Officer | SOpen-market sale Common Stock | -1,695 | $1.97 | $3,339 | 739,744 | Sep 3, 2025 |
| Jun 12, 2025 | Frank E Thomas director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | Patrick V.j.j. Vink director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | Kathleen Tregoning director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | Cynthia Smith director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | John C Pottage Jr director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | Ankit Mahadevia director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 709,866 | Jun 16, 2025 |
| Jun 12, 2025 | Scott Thomas Jackson director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 75,000 | Jun 16, 2025 |
| Jun 12, 2025 | Milind Deshpande director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 91,454 | Jun 16, 2025 |
| May 2, 2025 | Esther Rajavelu See Remarks | AGrant or award Common Stock | +185,000 | $0.00 | $0 | 909,720 | May 6, 2025 |
| Feb 3, 2025 | Timothy Keutzer Chief Operating Officer | AGrant or award Common Stock | +266,139 | $0.00 | $0 | 797,976 | Feb 5, 2025 |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SOpen-market sale Common Stock | -3,974 | $0.78 | $3,100 | 794,002 | Feb 5, 2025 |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SOpen-market sale Common Stock | -27,643 | $0.78 | $22k | 766,359 | Feb 5, 2025 |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SOpen-market sale Common Stock | -24,920 | $0.78 | $19k | 741,439 | Feb 5, 2025 |
| Nov 7, 2024 | Esther Rajavelu CFO & CBO | SOpen-market sale Common Stock | -23,351 | $1.31 | $31k | 396,515 | Nov 12, 2024 |
| Nov 8, 2024 | Esther Rajavelu CFO & CBO | SOpen-market sale Common Stock | -17,245 | $1.30 | $22k | 379,270 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Milind Deshpandedirector
- Scott Thomas Jacksondirector
- Timothy KeutzerChief Operating Officer
- Ankit Mahadeviadirector
- John C Pottage Jrdirector
- Esther RajaveluSee Remarks
- Cynthia Smithdirector
- Frank E Thomasdirector
- Kathleen Tregoningdirector
- Patrick V.j.j. Vinkdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.